Neurocrine Biosciences
NBIX
#1457
Rank
S$15.96 B
Marketcap
$157.67
Share price
-4.42%
Change (1 day)
7.61%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Neurocrine Biosciences (NBIX) - Total debt

Total debt on the balance sheet as of September 2024 : S$0.33 Billion

According to Neurocrine Biosciences 's latest financial reports the company's total debt is S$0.33 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Neurocrine Biosciences - Total debt on balance sheet (from 1996 to 2024)

Total debt by year

Year Total debt Change
2023-12-31S$0.56 B60.53%
2022-12-31S$0.35 B-40.8%
2021-12-31S$0.59 B9.15%
2020-12-31S$0.54 B-18.35%
2019-12-31S$0.66 B25.87%
2018-12-31S$0.53 B7.36%
2017-12-31S$0.49 B
2009-12-31S$16.18 M-26.49%
2008-12-31S$22.01 M929.73%
2007-12-31S$2.13 M-97.4%
2006-12-31S$82.25 M-16.84%
2005-12-31S$98.9 M-8.32%
2004-12-31S$0.10 B74.28%
2003-12-31S$61.89 M349.58%
2002-12-31S$13.76 M30.78%
2001-12-31S$10.52 M56.96%
2000-12-31S$6.7 M29.95%
1999-12-31S$5.16 M4.21%
1998-12-31S$4.95 M83.61%
1997-12-31S$2.69 M20.47%
1996-12-31S$2.23 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
S$0.99 B 195.49%๐Ÿ‡บ๐Ÿ‡ธ USA
S$10.21 B 2,926.01%๐Ÿ‡ฌ๐Ÿ‡ง UK
S$0.79 M-99.77%๐Ÿ‡บ๐Ÿ‡ธ USA
S$41.78 B 12,278.56%๐Ÿ‡บ๐Ÿ‡ธ USA
S$95.43 B 28,173.27%๐Ÿ‡บ๐Ÿ‡ธ USA
S$89.43 B 26,398.41%๐Ÿ‡บ๐Ÿ‡ธ USA
S$0.38 B 13.46%๐Ÿ‡บ๐Ÿ‡ธ USA
S$24.94 M-92.61%๐Ÿ‡บ๐Ÿ‡ธ USA